"AI Drug Delivery's First Stock" Jitai Technology (METiS) officially passes the Hong Kong Stock Exchange hearing

Mars Finance News, April 20: “First AI drug delivery stock,” Jitai Technology (METiS), has officially passed the Hong Kong Stock Exchange hearing. The joint sponsors are Furey, DBS Asia, and CITIC Securities (Hong Kong). Founded in 2020 by a team of MIT scientists, the company leverages its proprietary world’s first AI nanodelivery platform, NanoForge, compressing the R&D timeline for targeted dosage form development from several years down to 2–3 months. It has already achieved precise delivery to 8 types of organs. Its in-development pipeline covers sectors such as tumors and the CNS, and it has cumulatively filed 217 patent applications.

In financial terms, in 2025 revenue is set to surge by nearly 70 times year over year to 105 million yuan, with a gross margin of 98.2%. Losses continue to narrow, and cash on hand exceeds 1.1 billion yuan. The company has collaborated with more than 30 global pharmaceutical companies, and its “platform + product” dual-engine model has been validated. After listing, it will join Jing Tai Technology and Zaiying Intelligent at the Hong Kong Stock Exchange, becoming the fastest market debutant for commercialization among the “three little dragons” of AI pharmaceuticals. (Kegu Bao report)